CytoDyn Reports Preliminary Results from First Five Patients in Phase 2 NASH Open Label Leronlimab Trial. Lower Fatty Deposits in All 5 Patients by as Much as 45% and Lower Fibrosis in 4 Patients by as Much as 10% Compared to Baseline.

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs